176 Results for "

CD4 T cell

" in MedChemExpress (MCE) Product Catalog:
Products (176)

176 Results for "CD4 T cell" in MCE Product Catalog:

Cat. No.: HY-B0426AS2
Synonyms: ALO4943A-d6 hydrochloride; KW4679-d6 hydrochloride
Olopatadine-d6 (ALO4943A-d6; KW4679-d6) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
loading...
    loading...
Cat. No.: HY-171881
CAS No.: 864686-48-6
Target:  

GSK-3 DYRK

BI-5521 is an orally active GSK-3 inhibitor with an IC50 of 1.1 nM against GSK-3β. BI-5521 targets the two GSK-3 isoforms with similar potency and exhibits potent inhibitory activity against DYRK1A. By modulating GSK-3 activity, BI-5521 inhibits tumor proliferation and cancer cell growth, exerts cytotoxic effects, and reduces cancer cell viability. It shows consistent chemosensitivity across all subtypes of rhabdomyosarcoma, produces synergistic growth inhibitory effects when combined with SOS1 inhibitors, reduces oral glucose levels, regulates the myofibroblast differentiation pathway, decreases the nuclear localization of YAP/SMAD2/3, and lowers the positive rate of α-SMA in fibroblasts without affecting the apoptosis of CD4 + T cells. BI-5521 can be used in the research of non-small cell lung cancer, pleomorphic rhabdomyosarcoma, type 2 diabetes, pancreatic ductal adenocarcinoma, Alzheimer's disease, bipolar disorder, and metabolic dysfunction-associated steatotic liver disease .
loading...
    loading...
Cat. No.: HY-169335
Target:  

HIV

Research Areas:  

Infection

HIV-1 inhibitor-77 (compound 13) is a HIV-1 inhibitor. HIV-1 inhibitor-77 can neutralize all three tested viruses with the IC50 values of 0.14 μM, 8.28 μM and 2.92 μM for HIV-1CH58TF , HIV-1 JRFL and HIV-1 AD8, respectively .
loading...
    loading...
Cat. No.: HY-P99382
CAS No.: 2039148-04-2
Synonyms: JTX 2011; 37A10

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response .
loading...
    loading...
Cat. No.: HY-123312
CAS No.: 388604-55-5
Synonyms: CK-0993548
Target:  

Arp2/3 Complex HIV

Research Areas:  

Infection

CK-548 (CK-0993548) is a Arp2/3 complex inhibitor with the IC50 of 11 μM. CK-548 inhibits HIV-1 nuclear migration and infection .
loading...
    loading...
Cat. No.: HY-P990857

Target:  

Integrin

Research Areas:  

Inflammation/Immunology

Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody inhibitor, targeting to human CD54/ICAM-1. Anti-CD54/ICAM-1 Antibody (R6-5-D6) can block CD54 binding to its ligand Lymphocyte Function-Associated Antigen 1 (LFA-1). Anti-CD54/ICAM-1 Antibody (R6-5-D6) can be used for the researches of inflammation and immunology .
loading...
    loading...
Cat. No.: HY-P990839

Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human IFNγ. Anti-IFNγ Antibody (B133.5) can neutralize human IFNγ (interferon gamma). Anti-IFNγ Antibody (B133.5) can be used for the research of immunology .
loading...
    loading...
Cat. No.: HY-P990249

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse DR5/CD262 Antibody (MD5-1) is an anti-mouse DR5/CD262 IgG monoclonal antibody. Anti-Mouse DR5/CD262 Antibody (MD5-1) can eliminate myeloid derived suppressor cells (MDSCs) and enhance T cell anti-tumor immunity. Anti-Mouse DR5/CD262 Antibody (MD5-1) can be used for research on cancer such as gastric and colon cancer .
loading...
    loading...
Cat. No.: HY-P990837

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1 κ chimeric antibody inhibitor, targeting to human IL-4. Anti-IL-4 Antibody (MP4-25D2) can neutralize human IL-4 (interleukin-4). Anti-IL-4 Antibody (MP4-25D2) can be used for the inflammation and immunology .
loading...
    loading...
Cat. No.: HY-B0689B
CAS No.: 2563866-80-6
Synonyms: MK-639 ethanolate; L735524 ethanolate
Research Areas:  

Infection Cancer

Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CL pro inhibitor .
loading...
    loading...
Cat. No.: HY-P991307

Research Areas:  

Cancer

BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
loading...
    loading...
Cat. No.: HY-P991214
CAS No.: 339986-90-2
Synonyms: EMD 273066; huKS-IL2

Target:  

Interleukin Related

Research Areas:  

Cancer

Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
loading...
    loading...
Cat. No.: HY-171860
CAS No.: 3066894-28-5
Target:  

PROTACs HIV

Research Areas:  

Infection Cancer

FC-14369 is a PROTAC degrader targeting the HIV-1 Nef protein, with a DC50 value of 160 nM. Through its bifunctional structure, FC-14369 binds to Nef and the Cereblon E3 ubiquitin ligase, induces Nef ubiquitination and proteasomal degradation, restores the expression of cell-surface CD4 and MHC-I, and inhibits HIV-1 replication. FC-14369 can be used in research on HIV infection and AIDS. FC-14369 is applicable to studies related to HIV-1 infection .
loading...
    loading...
Cat. No.: HY-P991112

Research Areas:  

Infection

Anti-Mouse CD8α Antibody (YTS169.4) is an IgG2 monoclonal antibody targeting mouse CD8α. Anti-Mouse CD8α Antibody (YTS169.4) rapidly depletes or downregulates CD8 + T cells in the spleens of Biozzi AB/H mice. Anti-Mouse CD8α Antibody (YTS169.4) is applicable to research related to hepatitis B virus infection . Recommended isotype control: Rat IgG2b kappa, Isotype Control (HY-P990682).
loading...
    loading...
Cat. No.: HY-111485
CAS No.: 1820889-23-3
Purity:  98.29%
Synonyms: INCB-057643
Research Areas:  

Cancer

Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-111485R
CAS No.: 1820889-23-3
Synonyms: INCB-057643 (Standard)
Ertabresib (Standard) (INCB-057643 (Standard)) is the analytical standard of Ertabresib (HY-111485). This product is intended for research and analytical applications. Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer .
loading...
    loading...